Hope S. Rugo, MD

Articles

100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

Alexandra Vitko;Pamela K Ginex;Kelli Thoele;Qinli Lily Ma;Astra Liepa;Wambui Gathirua-Mwangi;Elyse Hall Panjic, PharmD, BCOP;Engels Chou;Jodi L Taraba;Hilary Ellis;Charlotte Clewes;Joanna de Courcy;Hope S. Rugo, MD

April 15th 2025

Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.

Elacestrant With Targeted Agents May Overcome ET Resistance in Breast Cancer

Hope S. Rugo, MD

December 16th 2024

Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.

Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.

Elacestrant Plus CDK4/6i May Optimize ESR1+ Breast Cancer Outcomes

Hope S. Rugo, MD

December 15th 2024

Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

Adam M. Brufsky, MD, PhD;Xianchen Liu;Benjamin Li;Lynn McRoy;Connie Chen;Doris Makari;Rachel M. Layman;Hope S. Rugo, MD

August 20th 2024

29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Erika P. Hamilton, MD;Sara A. Hurvitz, MD;Sara M. Tolaney, MD, MPH;Virginia Kaklamani, MD, DSc;Paula Muñoz Romero;Shannon Matheny;Kathy Puyana Theall;Joyce A. O’Shaughnessy

July 21st 2024

Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.

Managing AEs Associated With Capivasertib Combo in HR+/HER2– Breast Cancer

Hope S. Rugo, MD

June 6th 2023

Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.

11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above

Adam M. Brufsky, MD, PhD;Xianchen Liu;Benjamin Li;Lynn McRoy;Connie Chen;Rachel M. Layman;Hope S. Rugo, MD

April 28th 2023

48 Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2– Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) by HER2 Immunohistochemistry (IHC) Status in the Phase 3 TROPiCS-02 Study

Sara M. Tolaney, MD, MPH;Peter Schmid, MD;Javier Cortes;Frederik Marmé;Hope S. Rugo, MD;Mafalda Oliveira;Delphine Loirat;Komal Jhaveri;Oh Kyu Yoon;Monica Motwani;Hao Wang;Rosemary Delaney;Aditya Bardia, MD, MPH

April 27th 2023

53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Frederik Marmé;Javier Cortes;Peter Schmid, MD;Delphine Loirat;Olivier Trédan;Eva Ciruelos;Florence Dalenc;Patricia Gómez Pardo;Komal L. Jhaveri;Rosemary Delaney;Theresa Valdez;Hao Wang;Wendy Verret;Sara M. Tolaney, MD, MPH

April 27th 2023

55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Javier Cortes;Giuseppe Curigliano;Erika P. Hamilton, MD;Sara A. Hurvitz, MD;Sibylle Loibl;Simona Scartoni;Tarek Sahmoud, MD;Krzysztof J. Grzegorzewski;Nassir Habboubi;Joyce A. O’Shaughnessy

April 27th 2023

54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)

Hope S. Rugo, MD;Joyce O'Shaughnessy, MD;Komal Jhaveri;Sara M. Tolaney, MD, MPH;Fatima Cardoso;Aditya Bardia, MD, MPH;Purnima Pathak;Sina Haftchenary;Peter A. Fasching

April 26th 2023

Future Outlook for Treatment of HER2-Low and Triple-Negative Breast Cancers

Hope S. Rugo, MD;Paolo Tarantino, MD

March 21st 2023

Hope S. Rugo, MD, FASCO, and Paolo Tarantino, MD, offer closing remarks on the growing field of HER2-low and triple-negative breast cancer.

Treatment of HER2-Low Triple-Negative Breast Cancer

Hope S. Rugo, MD;Paolo Tarantino, MD

March 21st 2023

Breast cancer experts talk through their approaches to treating HER2-low triple-negative breast cancer.

PD-L1 Positivity in Triple-Negative Breast Cancer

Hope S. Rugo, MD;Paolo Tarantino, MD

March 14th 2023

Experts on breast cancer give an overview to treating PD-L1-positive triple-negative breast cancer.

Hope S. Rugo, MD, an expert on breast cancer

BRCA Mutations in Triple-Negative Breast Cancer

Hope S. Rugo, MD;Paolo Tarantino, MD

March 14th 2023

Hope S. Rugo, MD, FASCO, discusses how BRCA mutations change the treatment approach for triple-negative breast cancer.

Treatment Approaches for Early Breast Cancer Progression

Hope S. Rugo, MD;Paolo Tarantino, MD

March 7th 2023

Paolo Tarantino, MD, explains his approach to treating patients with triple-negative breast cancer who progress early after completing adjuvant therapy.

Antibody-Drug Conjugates in TNBC: ASCENT and DESTINY-Breast04

Hope S. Rugo, MD;Paolo Tarantino, MD

March 7th 2023

An overview of antibody-drug conjugates in the recurrent triple-negative breast cancer treatment landscape, and the ASCENT and DESTINY-Breast04 trials.

Treatment Approaches for Recurrent Triple-Negative Breast Cancer

Hope S. Rugo, MD;Paolo Tarantino, MD

February 28th 2023

Expert oncologists discuss treatment options in the setting of recurrent triple-negative breast cancer.

Residual Disease and HER2-Low Status in Triple-Negative Breast Cancer

Hope S. Rugo, MD;Paolo Tarantino, MD

February 28th 2023

Hope S. Rugo, MD, FASCO, and Paolo Tarantino, MD compare treatment approaches for HER2-low and triple-negative breast cancer.

Neoadjuvant Therapy Options in Triple-Negative Breast Cancer

Hope S. Rugo, MD;Paolo Tarantino, MD

February 24th 2023

Paolo Tarantino, MD, an expert on breast cancer, gives an overview of neoadjuvant treatment options for triple-negative breast cancer.

Patient Profile: A 52-Year-Old Woman with Triple-Negative Breast Cancer

Hope S. Rugo, MD;Paolo Tarantino, MD

February 24th 2023

Breast cancer experts Hope S. Rugo, MD, FASCO, and Paolo Tarantino, MD, present the case of a 52-year-old woman with triple-negative breast cancer and provide their initial thoughts.

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

Adam M. Brufsky, MD, PhD;Hannah M. Linden, MD;Hope S. Rugo, MD;Joyce A. O’Shaughnessy;Robert H. Getzenberg;K. Gary Barnette;Domingo Rodriguez;Mitchell Steiner;Erica L. Mayer, MD, MPH

April 18th 2022

8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination Therapy

Elgene Lim, MBBS, FRACP, PhD;Adam M. Brufsky, MD, PhD;Hope S. Rugo, MD;Charles L. Vogel, MD, FACP;Joyce A. O’Shaughnessy;Robert H. Getzenberg;K. Gary Barnette;Domingo Rodriguez;Mitchell Steiner;Hannah M. Linden, MD

April 18th 2022

Breast Cancer Experts Look Ahead to Exciting Programs in 2023

Hope S. Rugo, MD;Paolo Tarantino, MD

February 21st 2022

Hope S. Rugo, MD, MBA, and Paolo Tarantino, MD, give a preview to a first-of-its-kind Tweet Chat taking place in January 2023.

Dr. Hope S. Rugo on the SOPHIA Trial in HER2+ Breast Cancer

Hope S. Rugo, MD

June 12th 2019

Cancer Network spoke with Hope S. Rugo, MD, of the University of California, San Francisco, about the results of the phase III SOPHIA trial in HER2-positive breast cancer.

1 2 >